Kenya NGO saves turtles from nets, plastic and rising tides
On the beach of the seaside town of Watamu, it takes four men to heave the huge Loggerhead sea turtle into the back of a car.
She has just been saved from a fishing tackle and will be taken to a nearby clinic to be checked for injuries, then weighed, tagged and released back into the sea.
A Kenyan NGO, Local Ocean Conservation (LOC), has been doing this work for almost three decades and has carried out some 24,000 rescues.
"Every time I release a turtle, it's a really great joy for me. My motivation gets stronger and stronger," said Fikiri Kiponda, 47, who has been part of LOC's 20-odd staff for 16 years.
LOC began life in 1997 as a group of volunteers who hated seeing the creatures being eaten or dying in nets.
Turtles are still poached for their shells, meat and oil.
But through the charity's awareness campaigns in schools and villages, "perceptions have significantly changed", said Kiponda.
LOC, which relies mostly on donations, compensates fishermen for bringing them injured turtles.
More than 1,000 fishermen participate in the scheme and mostly do so for the sake of conservation, the charity emphasises, since the reward does not offset the hours of lost labour.
- Floating turtles -
At the NGO's nearby clinic, health coordinator Lameck Maitha, 34, says turtles are often treated for broken bones and tumours caused by a disease called Fibropapillomatosis.
One current in-patient is Safari, a young Olive Ridley turtle around 15 years old -- turtles can live beyond 100 -- transported by plane from further up the coast.
She arrived in a dire state, barely alive and with a bone protruding from her flipper, which ultimately had to be amputated -- likely the result of fighting to free herself from a fisherman's net.
Safari has been recovering well and the clinic hopes she can return to the sea.
Other frequent tasks include removing barnacles that embed themselves in shells and flippers, weakening their host.
But a growing danger is plastic pollution.
If a turtle eats plastic, it can create a blockage that in turn creates gas, making the turtle float and unable to dive.
In these cases, the clinic gives the turtle laxatives to clear out its system.
"We are seeing more and more floating turtles because the ocean has so much plastic," said Maitha.
- Survivors -
LOC also works to protect 50 to 100 nesting sites, threatened by rising sea levels.
Turtles travel far and wide but always lay their eggs on the beach where they were born, and Watamu is one of the most popular spots.
Every three or four years, they produce hundreds of eggs, laid during multiple sessions over several months, that hatch after around 60 days.
The charity often relocates eggs that have been laid too close to the sea.
Marine biologist Joey Ngunu, LOC's technical manager, always calls the first to appear Kevin.
"And once Kevin comes out, the rest follow," he said with a smile, describing the slow, clumsy procession to the water, preferably at night to avoid predators as much as possible.
Only one in a thousand reaches adulthood of 20-25 years.
"Living in the sea as a turtle must be crazy. You have to face so many dangers, fish and poachers, and now human pressure with plastic and commercial fishing," he said.
"Turtles are definitely survivors."
str-jf/jcp/er/rbu/kjm
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
Turtles could hold key to curing cancer
Turtles could hold the key to finding a cure for cancer, researchers have found. Creatures that are both large and long-lived typically face a higher risk of getting the disease, but turtles seem to defy that pattern. The reason may lie in their strong defence against cell damage, slow metabolism, which reduces cellular stress, and unique genes that protect against cancer, researchers said. In the study, scientists from the universities of Nottingham and Birmingham analysed medical records of autopsies from hundreds of zoo turtles, including some from Chester Zoo in Cheshire. They found that 1 per cent had been affected by cancer, far less than in mammals or birds. It also discovered that, when tumours did appear, they almost never spread. Some turtle species – which included tortoises – have life spans beyond 100. The Galapagos and Aldabra giant tortoises, for example, have lived beyond 150. In April, a female of the species became a first-time mother at the age of 100 in Philadelphia Zoo. Credit: Philadelphia Zoo Digital The researchers said the findings highlighted how essential it was to protect endangered species. Dr Ylenia Chiari, one of the authors of the study from the school of life sciences at the University of Nottingham, said: 'Turtles, especially iconic species like Galapagos and Aldabra giant tortoises, are famous for living long lives and growing to tremendous sizes. 'You'd expect that to mean more cancer, but our study, which combines decades of zoo records with previous research, shows how incredibly rare cancer is in these animals. 'It highlights turtles as an untapped model for understanding cancer resistance and healthy ageing, and it shows the vital role zoos play in advancing science through collaboration.' Dr Scott Glaberman, from the University of Birmingham, added: 'Biodiversity has so much to teach us about how the world works. 'While fascinating in their own right, extreme species like giant tortoises may have already solved many of the problems humans face, including those related to ageing and cancer. That makes biodiversity doubly worthy of protection.' Dr Helena Turner, the research officer at Chester Zoo, said: 'It's fantastic to see these efforts not only contribute to advancing scientific knowledge around cancer resistance but also support vital conservation work to protect these remarkable species that may hold keys to medical breakthroughs benefiting both wildlife and humans.' The study was published in the journal BioScience. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.


CNN
6 days ago
- CNN
First malaria drug for newborns and young infants expected to be approved in Africa within weeks
The approval of the first malaria treatment for newborns and young infants could lead to imminent widespread use in Africa, drugmaker Novartis said Tuesday. The drug, known as Coartem Baby or Riamet Baby in some countries, has been approved by Swiss authorities for use in babies weighing between 2 kilograms (4 pounds, 6 ounces) and 5 kilograms (11 pounds) and is formulated to be easy for them to take, Novartis said. Coartem Baby already has approval in the West African nation of Ghana and Novartis said it now expects eight African countries to grant their own approvals within 90 days. The countries – Burkina Faso, Cote d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Tanzania and Uganda – also participated in the assessment of the drug. Vas Narasimhan, chief executive of Novartis, said in a news release that this first clinically proven malaria treatment for newborns and young babies ensures 'even the smallest and most vulnerable can finally receive the care they deserve.' Until now, the smallest babies have been treated for malaria, a potentially deadly disease spread by mosquitoes, with medications designed for older children. Novartis, the Swiss pharmaceutical corporation behind the newly approved drug, says this can expose newborns to the risk of overdose and toxicity. 'Most clinical trials have historically excluded babies under six months old,' Novartis spokesman Ruairidh Villar told CNN. There were 263 million cases of malaria and 597,000 deaths in 2023 – nearly all of them in Africa, according to World Health Organization data. Children under the age of 5 accounted for about three in four malaria deaths in the region. The medicine was developed by Novartis in collaboration with the Medicines for Malaria Venture (MMV), a Switzerland-based not-for-profit organization. Novartis told CNN that it plans to 'roll out the medicine in the coming weeks on a largely not-for-profit basis.' 'Malaria is one of the world's deadliest diseases, particularly among children. But with the right resources and focus, it can be eliminated,' said Martin Fitchet, chief executive of MMV. 'The approval of Coartem Baby provides a necessary medicine with an optimized dose to treat an otherwise neglected group of patients and offers a valuable addition to the antimalarial toolbox.'


CNN
6 days ago
- CNN
First malaria drug for newborns and young infants expected to be approved in Africa within weeks
The approval of the first malaria treatment for newborns and young infants could lead to imminent widespread use in Africa, drugmaker Novartis said Tuesday. The drug, known as Coartem Baby or Riamet Baby in some countries, has been approved by Swiss authorities for use in babies weighing between 2 kilograms (4 pounds, 6 ounces) and 5 kilograms (11 pounds) and is formulated to be easy for them to take, Novartis said. Coartem Baby already has approval in the West African nation of Ghana and Novartis said it now expects eight African countries to grant their own approvals within 90 days. The countries – Burkina Faso, Cote d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Tanzania and Uganda – also participated in the assessment of the drug. Vas Narasimhan, chief executive of Novartis, said in a news release that this first clinically proven malaria treatment for newborns and young babies ensures 'even the smallest and most vulnerable can finally receive the care they deserve.' Until now, the smallest babies have been treated for malaria, a potentially deadly disease spread by mosquitoes, with medications designed for older children. Novartis, the Swiss pharmaceutical corporation behind the newly approved drug, says this can expose newborns to the risk of overdose and toxicity. 'Most clinical trials have historically excluded babies under six months old,' Novartis spokesman Ruairidh Villar told CNN. There were 263 million cases of malaria and 597,000 deaths in 2023 – nearly all of them in Africa, according to World Health Organization data. Children under the age of 5 accounted for about three in four malaria deaths in the region. The medicine was developed by Novartis in collaboration with the Medicines for Malaria Venture (MMV), a Switzerland-based not-for-profit organization. Novartis told CNN that it plans to 'roll out the medicine in the coming weeks on a largely not-for-profit basis.' 'Malaria is one of the world's deadliest diseases, particularly among children. But with the right resources and focus, it can be eliminated,' said Martin Fitchet, chief executive of MMV. 'The approval of Coartem Baby provides a necessary medicine with an optimized dose to treat an otherwise neglected group of patients and offers a valuable addition to the antimalarial toolbox.'